3,981 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by ClearAlpha Technologies LP

ClearAlpha Technologies LP bought a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,981 shares of the biopharmaceutical company’s stock, valued at approximately $332,000.

Other large investors also recently added to or reduced their stakes in the company. J. Safra Sarasin Holding AG lifted its stake in shares of Intra-Cellular Therapies by 9.7% in the 4th quarter. J. Safra Sarasin Holding AG now owns 30,564 shares of the biopharmaceutical company’s stock valued at $2,553,000 after purchasing an additional 2,693 shares during the last quarter. Stifel Financial Corp boosted its stake in shares of Intra-Cellular Therapies by 3.0% during the 4th quarter. Stifel Financial Corp now owns 34,210 shares of the biopharmaceutical company’s stock worth $2,857,000 after acquiring an additional 998 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in Intra-Cellular Therapies by 6,555.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 15,840 shares of the biopharmaceutical company’s stock worth $1,323,000 after purchasing an additional 15,602 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Intra-Cellular Therapies by 1.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 84,391 shares of the biopharmaceutical company’s stock worth $7,048,000 after purchasing an additional 1,186 shares during the period. Finally, First Trust Advisors LP grew its holdings in Intra-Cellular Therapies by 12.6% during the fourth quarter. First Trust Advisors LP now owns 766,134 shares of the biopharmaceutical company’s stock valued at $63,987,000 after purchasing an additional 85,883 shares during the last quarter. 92.33% of the stock is owned by institutional investors.

Intra-Cellular Therapies Stock Performance

NASDAQ ITCI opened at $131.87 on Monday. Intra-Cellular Therapies, Inc. has a 1-year low of $64.09 and a 1-year high of $131.98. The firm has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. The company has a 50 day moving average of $130.76 and a 200-day moving average of $106.44.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Ratings Changes

ITCI has been the topic of a number of research analyst reports. Piper Sandler reiterated a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Mizuho lowered shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Eleven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $109.70.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.